Samsung BioLogics Co (XKRX:207940) ROCE % : 12.27% (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Samsung BioLogics Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Samsung BioLogics Co's annualized ROCE % for the quarter that ended in Dec. 2024 was 12.27%.

Samsung BioLogics Co ROCE % Historical Data

The historical data trend for Samsung BioLogics Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Samsung BioLogics Co ROCE % Chart

Samsung BioLogics Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

5.10

9.07

11.14

9.89

11.19

Samsung BioLogics Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															12.68	8.62	15.65	9.45	12.27

Samsung BioLogics Co ROCE % Calculation

Samsung BioLogics Co's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	1420108.926	/	( ( (16046197.209 - 4157860.817)	+	(17336296.35 - 3853188.426) )	/ 2 )
	=	1420108.926	/	( (11888336.392	+	13483107.924)	/ 2 )
	=	1420108.926	/	12685722.158
	=	11.19 %

Samsung BioLogics Co's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	1592338.852	/	( ( (16026339.69 - 3563759.58)	+	(17336296.35 - 3853188.426) )	/ 2 )
	=	1592338.852	/	( ( 12462580.11	+	13483107.924 )	/ 2 )
	=	1592338.852	/	12972844.017
	=	12.27 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Samsung BioLogics Co (XKRX:207940) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Samsung BioLogics Co ROCE % Related Terms

Thank you for viewing the detailed overview of Samsung BioLogics Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Samsung BioLogics Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Samsung BioLogics Co Ltd (XKRX:207940) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

125, Cheomdan-daero, Yeonsu-gu, Incheon, KOR

Website

https://www.samsungbiologics.com

Founded in 2011, Samsung Biologics is a South Korean contract development and manufacturing organization with a global client base. Europe and the US contribute 90% of its total revenue. It provides end-to-end development and manufacturing services from cell line developments to final commercial manufacturing. As of 2023, Samsung Biologics had a total production capacity of 604,000 liters, one of the largest in the world. Its CDMO services account for 72.4% of its total revenue. The balance comes from subsidiary Samsung Bioepis, acquired in 2022. Samsung Bioepis is involved in developing and manufacturing biosimilars.

Samsung BioLogics Co Headlines

No Headlines